Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Accellacare Wilmington

Neither a doctor nor a teaching hospital

Research payments

$526,449

95 payments

Through program year 2025, Accellacare Wilmington is reported as receiving $526,449 in research payments, across 95 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $147,538 33
2024 Research $185,102 6
2023 Research $24,628 23
2022 Research $153,307 31
2021 Research $15,874 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. E.R. Squibb & Sons, L.L.C. $292,172 4 payments
  2. Merck Sharp & Dohme Corporation $147,477 6 payments
  3. Pfizer Inc. $86,799 85 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis $252,457 2 payments
  2. A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction $147,477 6 payments
  3. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis $39,716 2 payments
  4. A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $25,543 8 payments
  5. An Interventional Efficacy and Safety Phase 2 Randomized Doubleblind 2Arm Study to Investigate A Repeat 5Day Course of Nirmatrelvirritonavir Compared to Placeboritonavir in Participants at Least 12 Years of Age With Rebound of Covid19 Symptoms and Rapid Antigen Test Positivity $16,335 6 payments
  6. A Study to Evaluate the Safety Tolerability and Immunogenicity of Combined Vaccine Candidates Against Infectious Respiratory Illnesses Including Covid19 and RSV in Healthy Individuals $7,130 2 payments
  7. A Phase 12 Randomized Observerblind Study to Evaluate the Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Varicella Zoster Virus in Healthy Individuals $5,319 8 payments
  8. A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $4,712 12 payments
  9. A Phase 1 Randomized Openlabel Trial to Evaluate the Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age $3,639 4 payments
  10. A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $3,409 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record